儿童脑瘤的分子基础:临床影响的综述
Elias Antoniades1, Nikolaos Keffes1, Stamatia Vorri2
1Second Department of Neurosurgery, Aristotle University School of Medicine, 546 36 Thessaloniki, Greece.
Cancers
|May 14, 2025
概括
儿科中枢神经系统 (CNS) 瘤是由异常细胞信号传递引起的. 像MAPK,氨酸激酶受体和表观遗传调节器这样的分子通路是各种中枢神经系统瘤类型的关键驱动因素.
科学领域:
- 儿科神经瘤学 儿童神经瘤学
- 中枢神经系统瘤的分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 中枢神经系统 (CNS) 瘤是最常见的儿科固体恶性瘤.
- 异常的细胞信号通路,包括基激活蛋白激酶 (MAPK) 和氨酸激酶受体,都与瘤发生有关.
- 表观遗传失调,特别是涉及组织蛋白,在高度质瘤中起着重要作用.
研究的目的:
- 审查各种儿科中枢神经系统 (CNS) 瘤的分子基础.
- 突出多样化的遗传和表观遗传变化驱动儿科中枢神经系统瘤发生.
- 为儿童中枢神经系统恶性瘤的分子景观提供概述.
主要方法:
- 关于儿童中枢神经系统瘤分子变化的文献综述.
- 对遗传突变和表观遗传变化的分析.
- 按瘤类型对分子事件的分类.
主要成果:
- 低度质瘤涉及MAPK通路和氨酸激酶受体.
- 高度质瘤的特点是表观遗传失调.
- 胚胎瘤 (骨髓母细胞瘤,非典型的形形瘤,带有多层章的胚胎瘤) 在转录调节,染色质重塑和翻译方面表现出突变.
- 膜瘤涉及NFkB或Hippo通路 (上) 或DNA损伤修复分子 (后A型).
- 细菌瘤表现出KIT受体突变.
结论:
- 儿科中枢神经系统瘤表现出广泛的分子变化.
- 了解这些分子驱动因素对于有针对性的治疗和改善预后至关重要.
- 表观遗传和信号通路失调是儿科中枢神经系统瘤发生的核心因素.
更多相关视频
相关概念视频
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410